CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of hepatobiliary cancers.
  
  LEARNING OBJECTIVES

  • Consider age, performance status, degree of liver function and other clinical and logistical factors in the selection of first-line therapy for patients with unresectable or metastatic hepatocellular carcinoma (HCC).
  • Appreciate Phase III data leading to the FDA approval of novel first-line treatment strategies for unresectable or metastatic HCC, and discuss how these can be optimally integrated into the clinical care of patients.
  • Establish an evidence-based approach to the selection and sequencing of available therapeutic options for patients with progressive HCC.
  • Evaluate available data documenting the efficacy of anti-PD-L1 antibody therapy in combination with chemotherapy as first-line treatment for advanced biliary tract cancers, and consider the role of this therapeutic strategy.
  • Recognize the molecular heterogeneity of cholangiocarcinomas and other biliary tract cancers, and appreciate the biologic rationale for efforts to exploit documented molecular abnormalities in these diseases.
  • Assess key data sets supporting the FDA approvals of fibroblast growth factor receptor (FGFR) inhibitors for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement, and consider how these agents can be appropriately and safely integrated into the clinical management algorithm.
  • Recall available and emerging data with investigational agents and strategies currently in clinical testing for hepatobiliary cancers, and refer eligible patients for trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty and moderator reported relevant financial relationships with ineligible entities:
  
  Richard S Finn, MD
  Professor, Department of Medicine, Division of Hematology/Oncology
  David Geffen School of Medicine at UCLA
  Director, Signal Transduction and Therapeutics Program
  Jonsson Comprehensive Cancer Center at UCLA
  Los Angeles, California
  
  Advisory Committee: CStone Pharmaceuticals; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Hengrui Therapeutics Inc, Lilly, Merck, Pfizer Inc; Contracted Research (to Institution): Adaptimmune, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Eisai Inc, Genentech, a member of the Roche Group, Lilly, Merck, Pfizer Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Hengrui Therapeutics Inc; Speaker’s Bureau: Genentech, a member of the Roche Group.
  
  Lipika Goyal, MD, MPhil
  Director of Gastrointestinal Oncology
  Stanford Cancer Center
  Associate Professor
  Stanford University School of Medicine
  Palo Alto, California
  
  Advisory Board and Consulting Agreements: Alentis Therapeutics AG, Black Diamond Therapeutics Inc, Exelixis Inc, Genentech, a member of the Roche Group, H3 Biomedicine, Incyte Corporation, Kinnate Biopharma, Merck, QED Therapeutics, Servier Pharmaceuticals LLC, Sirtex Medical Ltd, Surface Oncology, Taiho Oncology Inc, TransThera Biosciences, Tyra Biosciences; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP.
  
  Professor Arndt Vogel, MD
  Managing Senior Consultant
  Department of Gastroenterology, Hepatology and Endocrinology
  Hannover Medical School
  Hannover, Germany
  
  Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Böhringer Mannheim, Bristol-Myers Squibb Company, BTG, Daiichi Sankyo Inc, Eisai Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merck Sharp & Dohme LLC, Pierre Fabre, Roche Laboratories Inc, Servier Pharmaceuticals LLC, Sirtex Medical Ltd, Taiho Oncology Inc, Terumo Medical Corporation; Speaker: Advanced Accelerator Applications, Amgen Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Böhringer Mannheim, Bristol-Myers Squibb Company, BTG, Daiichi Sankyo Inc, Eisai Inc, GlaxoSmithKline, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jiangsu Hengrui Medicine Co Ltd, Merck Sharp & Dohme LLC, Pierre Fabre, Roche Laboratories Inc, Servier Pharmaceuticals LLC, Sirtex Medical Ltd, Taiho Oncology Inc, Terumo Medical Corporation.
  
  MODERATOR
  
  Robin K (Katie) Kelley, MD
  Professor of Clinical Medicine, Division of Hematology/Oncology
  Helen Diller Family Comprehensive Cancer Center
  University of California, San Francisco (UCSF)
  San Francisco, California
  
  Advisory Board: Kinnate Biopharma; Advisory Board or Steering Committee (to Institution): Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Merck; Advisory Committee: Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Kinnate Biopharma, Merck; Research Funding to Institution: Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Partner Therapeutics, QED Therapeutics, Relay Therapeutics, Surface Oncology, Taiho Oncology Inc; Uncompensated Service on IDMC: Genentech, a member of the Roche Group, Merck.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Incyte Corporation, and Merck.
  
  Release date: February 2023
  Expiration date: February 2024